-

Solstice HealthCommunications’ Patient Journey Work is Published in Prestigious Journal

FAR HILLS, N.J.--(BUSINESS WIRE)--Solstice, a full-service, woman-owned, communications agency is excited to announce that its patient journey project has been documented and published in the May issue of the Orphanet Journal of Rare Diseases, the portal for rare diseases and orphan drugs. “Mapping the PIK3CA-Related Overgrowth Spectrum (PROS) Patient and Caregiver Journey Using a Patient-Centered Approach” explains how Solstice used its novel methodology to develop a patient engagement roadmap for PROS conditions. The article can be accessed online via PubMed (Orphanet J Rare Dis 2022 May 7;17(1):189. doi: 10.1186/s13023-022-02338-1.)

A large pharmaceutical company selected Solstice to develop this journey, which was created in concert with patients, caregivers, and advocates as key partners. The interactive visualization of the PROS journey identifies areas of unmet need, barriers to care, and education topics, and has been used as a core strategic planning tool for disease awareness and launch readiness. “This type of work, spearheaded by one of our Certified Health Education Specialists, is essential for pharmaceutical companies looking to understand the patient experience and areas of unmet need, particularly in the rare disease space,” according to Nanske Wood, President of Solstice.

Patient engagement is increasingly recognized as an integral part of patient-centered healthcare. A better understanding of the entire patient experience through this journey analysis method will help Pharma/Biotech develop the appropriate patient and caregiver strategies to effectively address educational and support needs.

To find out more regarding how this unique methodology could benefit your brand/marketing efforts, contact Nanske Wood at nwood@solsticehc.net or 973-879-3819.

About Solstice

Solstice is a full service, privately held WBENC and WOSB agency based in Far Hills, NJ. The philosophy, at the heart of our work is that “messaging” is not nearly enough and that customers of all kinds—HCPs as well as patients and families—must be engaged with a brand to drive change. Our engagement efforts are built on a keen understanding of customer needs and the clinical encounters between patients, caregivers, and HCPs. The end goal being to drive behavioral change among key stakeholders to positively impact the lives of patients.

Contacts

Nanske Wood
nwood@solsticehc.net
973-879-3819

More News From Solstice

Solstice Health Communications Is Now a Certified GSA Contractor

FAR HILLS, N.J.--(BUSINESS WIRE)--Solstice Health Communications is proud to announce that we are now a GSA certified government contractor (Contract 47QRAA23D006F) and able to do business with the federal government. We can help support your business needs from branding, strategy, digital activation, and all aspects of stakeholder engagement and execution. About Solstice: Solstice offers strong strategic, medical, and creative expertise. We are a woman-owned communications agency certified by...

Akron BioProducts Announces Launch of its Closed System Solutions™ line to Enable Seamless Integration of cGMP Ancillary Materials in Cell and Gene Therapy Manufacturing

BOCA RATON, Fla.--(BUSINESS WIRE)--Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed System Solutions™ (CSS) product line, aimed at functionally closing critical unit operations in cell and gene therapy manufacturing workflows. Akron’s industry-leading liquid Recombinant Human Interleukin-2 (rHu IL-2), Human AB Serum Converted from Octaplas®, and Human Serum Albumin 25% Solution ar...
Back to Newsroom